Drugs Made In America Acquisition Corp.

The immediate outflow of $99,336,016.67 significantly shrinks the capital base available to execute a business combination before the new April 2027 expiration. The mandatory monthly extension deposits create a recurring capital drain that sponsors must fund to maintain corporate existence, directly impacting post-combination equity value. The voting record—18,906,281 FOR against 4,892,646 AGAINST, achieving a 70.58% quorum—confirms strong shareholder turnout and explicit approval to continue operations despite the substantial cash reduction.

Beyond deal mechanics, the filing substantively restructures leadership compensation and corporate liability exposure, as stated by the Company. For Chief Financial Officer Saleem Elmasri (initially appointed November 17, 2025), the amended Statement of Work with Titan Advisory Services LLC retains operational duties at $3,500 monthly compensation, confirms unpaid amounts accrue as binding obligations, and adjusts equity compensation because Titan was never issued the originally stipulated 100,000 ordinary shares. The updated grant awards Elmasri 175,000 ordinary shares. For Chief Executive Officer Roger Bendelac (appointed February 28, 2026), whose compensation was initially undetermined, the Company executed a separate agreement with Aleutian Equity Holdings LLC. Bendelac receives $4,500 per month, broken down as $2,500 payable currently and up to $2,000 deferrable based on the Company’s cash flow, with deferred sums accruing as binding obligations. He is additionally allocated 250,000 ordinary shares. According to Exhibit 10.2, the agreement specifies indemnification covering securities claims (excluding gross negligence/fraud), limits liability to fees paid except in cases of fraud or willful misconduct, and requires dispute resolution through mediation followed by binding arbitration via AAA or JAMS in New York under New York governing law. These terms introduce specific cashflow-dependent liabilities and transaction-contingent share issuances that alter the post-merger capital stack, governance framework, and sponsorship cost structure.

These amendments directly govern redemption mechanics and capital preservation ahead of the Extraordinary General Meeting. Pushing the final deal deadline to April 29, 2027 and adjusting the monthly trust funding metric to $0.04 or $300,000 changes the cash-outflow pressure and extends the redemption window relative to the prior structure. Revised share counts and voting minimums alter the exact number of un-redemmed public shares required to approve the extension and satisfy quorum rules. Beyond procedural math and timeline shifts, the document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, or litigation.

This filing signals a near-complete collapse of the original sponsor structure and a rushed pivot to a new deal. The trust per-share value as of December 31, 2025, was $10.43. Shareholders must watch the April 27, 2026 vote on the extension and any redemption deadline closely, as the SPAC has negligible cash outside trust ($6,137 cash, $363,981 working capital deficit) and is dependent on BV Advisory's funding. The Power Analytics LOI at a $1 billion valuation is preliminary and may change materially.

Because the Board admits there is insufficient time to finalize terms with Power Analytics Global Corp. before April 29, 2026, the extension mechanism directly controls whether capital remains accessible for further negotiations or triggers liquidation ten business days post-April 29, 2026. The approximately $10.52 redemption valuation against a $10.51 market price creates immediate arbitrage parameters for public shareholders facing the April 23, 2026 tender cutoff. The Sponsor’s financial exposure—where founder shares would become worthless upon liquidation—aligns insider incentives with securing the two-thirds majority needed to activate monthly funding. The conditional, unpaid loan structure preserves trust balance flexibility while ensuring the Board retains sole discretion to halt extensions early if alternative paths emerge or execution stalls.

The filing anchors the merger at a $1,000,000,000 valuation and transparently defines redemption economics via the $25,000,000 to $50,000,000 minimum cash parameter, enabling precise modeling of post-combination liquidity and dilution. Contractual trust waivers shield public shareholder funds from target-related liabilities, while the conditional extension commitment mitigates timeline expiration risk. Advancement toward a Form S-4 formally triggers SEC scrutiny and the public shareholder proxy vote calendar, shifting the entity from preliminary interest to binding negotiation and regulatory compliance.

Deferred annual reporting directly impacts SPAC transparency and compliance tracking. Investors monitoring redemption windows, extension triggers, and sponsor fiduciary execution must await the actual 10-K delivery by the April 15, 2026 commitment date to verify net tangible assets, audit opinions, and Nasdaq listing standards. The CEO’s attribution of the delay to data compilation challenges, coupled with the assurance of current quarterly/periodic compliance, establishes a baseline for evaluating management’s disclosure cadence while leaving the timing of shareholder actions unresolved until financials are public.

Shareholders face an immediate decision point between executing the irrevocable redemption right before the March 25, 2026 deadline or retaining exposure to an extended strategic runway. The extension mechanism transfers incremental financing risk to the Sponsor each month, but because the exact monthly deposit amount remains redacted, investors cannot precisely model ongoing cash infusion levels or potential trust account erosion. Supermajority voting thresholds mean that broker non-votes or abstentions do not count against passage, potentially allowing the extension to advance even with significant public apathy. Should the proposal fail, the Board commits to liquidating within ten business days, distributing pro rata Trust balances after prioritizing creditor claims and deducting up to US$100,000 in winding-up costs, while warrant and insider equity interests expire worthless. The disclosure confirms active but confidential negotiations, raising the near-term probability of a definitive business combination agreement versus forced dissolution, though the Board explicitly warns there is no guarantee a suitable Target will be identified or that execution will occur by the Extended Date.

The structured funding schedule explicitly finances accounting, audit, Nasdaq compliance, proxy extension, and regulatory expenses outside the trust account, mechanically preserving public shareholder cash while extending the redemption window. However, the 35% conversion discount and 40% sponsor-equivalent economics provision fundamentally alter post-merger capitalization, introducing significant dilution and control realignment risks for existing holders. Strategically, Barksdale and Bendelac’s filing introduces a target identified as Power Analytics Global Corporation, described as an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions. While preliminary due diligence has commenced, Bendelac’s report explicitly states that no letter of intent, term sheet, or definitive agreement has been executed, meaning trust distribution timelines and merger feasibility remain entirely contingent on the six-month diligence milestone and successful negotiation of new bridge terms rather than audited financials, revenue projections, or binding valuation metrics.

Investors should treat the board’s explicit certification that the $241,292,436 trust account was insulated from the affiliate’s working capital irregularities as the controlling fact for redemption valuation purposes. By attributing the withdrawal misconduct solely to an affiliate’s working capital and confirming the main trust’s preservation, the CEO’s statement aims to prevent panic redemptions based on unfounded liquidity fears. Nevertheless, the disclosed sponsor conduct at an affiliate warrants scrutiny regarding related-party oversight, potential cross-collateralization risks, and the sponsor’s fiduciary reliability ahead of any business combination vote. Because the filing alters neither the merger timeline nor the redemption calendar, holders should continue tracking original deadlines, but may adjust their due diligence focus toward sponsor transparency and corporate governance controls.

While the 8-K does not update the redemption calendar, adjust the trust balance, or announce a target acquisition, the disclosure of sponsor-level working capital withdrawals and the resulting leadership turnover carry direct governance implications for deal execution and shareholder voting dynamics. The filing notes no changes to trust mechanics or extension timelines, but the sudden departure of the executive chair and CEO following disputed sponsor fund movements introduces operational friction that could delay proxy solicitations, extension votes, or merger negotiations. The board explicitly linked the executive terminations to the sponsor’s conduct, establishing a clear record for potential shareholder inquiries. The appointment of a 69-year-old incoming CEO with extensive corporate advisory and consulting experience—whose compensation package remains unsettled—leaves near-term fiduciary oversight and strategic decision-making unclarified for investors tracking sponsor behavior and deal progress.

Provides first detailed financial update post-IPO, showing trust account growth and per-share redemption value. Highlights the company's cash position and the approaching deadline (April 29, 2026, with possible extensions). Important for investors tracking redemption mechanics, trust value, and deal progress. The going concern disclosure and material weaknesses indicate risks.

This executive transition occurs while the company operates with a reported trust value of $10.71 per share, raising questions about cost structure, financial oversight continuity, and sponsor conduct as the entity navigates toward a business combination or potential redemption window. Outsourcing the principal financial and accounting function to a third-party advisory firm may streamline monthly operational burn but concentrates financial control risk in the $42,000 annual fee plus the immediate 100,000-share equity grant, diluting public float ahead of any shareholder vote or extension proposal. The reliance on external management for core fiduciary duties during pending deal execution warrants close monitoring by investors tracking redemption triggers, target acquisition readiness, and whether the sponsor intends to alter typical in-house CFO expectations to preserve cash through the transaction deadline.

For a SPAC with declared deal status, a delayed quarterly disclosure interrupts the information flow needed to validate whether operational cash preservation aligns with pre-merger planning or sponsor commitments. The registrant explicitly states there is no anticipated significant change in operating results relative to the last fiscal year, which limits immediate downside surprise risk for shareholders evaluating extension versus redemption choices. By invoking Rule 12b-25 and pledging submission within five calendar days of the missed deadline, the company aims to mitigate exchange delisting flags and preserve its standing as a reporting issuer while audit sign-off procedures conclude. Investors tracking sponsorship conduct will monitor whether this administrative lag correlates with broader valuation disputes, target diligence holdups, or auditor qualification concerns once the actual 10-Q is published, as timely transparency remains critical for shareholders exercising redemption rights before any business combination vote.

This is the first 10-Q since the IPO and provides the baseline financial position. The $10.22 trust per share is above the $10.00 IPO price, meaning redemptions would be at a premium if a deal is announced. The going concern note and material weakness signal operational risk. No business combination target has been identified.

This is the first post-IPO quarterly report for DMAA. The trust value per share ($10.12) provides the baseline for redemption calculations. The minimal cash on hand ($923) and working capital deficit indicate the SPAC is dependent on the sponsor's subscription receivable and working capital loans for ongoing operations. The disclosure of a material weakness in internal controls over financial reporting is a new red flag for investors. The going concern disclosure reinforces that the SPAC must complete a deal or liquidate within the 15-21 month window.

Late periodic filing notifications place SPACs on compliance watchlists and can temporarily restrict trading activity while the exchange reviews the cure timeline. For a deal-announced SPAC, delayed financial statements often reflect bottlenecks in auditor sign-offs or management certification processes that precede final business combination approvals and shareholder meetings. Although this notice does not update the trust balance or extend the merger deadline, the identified contact—Lynn Stockwell, Chief Executive Officer at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301—will oversee the upcoming submission, which typically contains the comprehensive financial disclosures required for proxy materials or prospectus supplements ahead of a de-SPAC transaction.

This is the first 10-K providing full trust mechanics, redemption terms, and sponsor conduct. Trust holds $10.05 per share. CEO's affiliation with a bankrupt entity (BGXX) is disclosed. Disclosure controls were deemed ineffective due to material weakness in segregation of duties. No target or substantive discussions have been initiated.

Closing the over-allotment option finalizes the public equity structure and immediately triggers the forfeiture reversal for founder shares, altering early-stage dilution dynamics. The documented $10.05 per-share redemption value establishes the current baseline accounting value for public shareholders considering early exits, exceeding the original $10.00 offering price. Formalizing the $6,900,000 deferred underwriting obligation and removing the $305,179 liability produces a verified post-IPO balance sheet benchmark before any acquisition activity begins. The unresolved $1,100,000 sponsor receivable represents a minor pending capital call that may affect near-term operating liquidity. The filing contains no announcements regarding merger candidates, deal progression, extension proposals, or specific shareholder vote dates, meaning redemption windows and business combination timelines remain governed exclusively by the original prospectus framework.

The filing bears directly on sponsor conduct and insider alignment metrics. The reported open-market sale of 5,698,363 shares by the company’s executive chairman and chief executive reduces disclosed insider concentration, while the paired 400,000-share purchase and offsetting disposition function as a non-economic mechanical entry that cancels out. No substantive claims concerning customer acquisition, revenue streams, addressable market size, proprietary technology, commercial partnerships, regulatory status, or pending litigation appear in this exhibit. All ownership tallies, trade dates, compensation titles, and share counts are attributed solely to the Form 4 submission itself.

This filing defines the hard redemption floor, capital structure, and expiration clock for public shareholders. The mandatory 15-month period (extendable to 21 months via sponsor cash injections) locks in the timeline before public shares become redeemable or the SPAC faces dissolution. The underwriters’ deferred fee waiver condition and the sponsor’s third-party indemnity commitment materially protect the per-share trust payout from creditor erosion or transaction cost drawdowns, ensuring the initial $10.05 benchmark is maintained absent market losses. The sponsor’s retention of 9,857,143 founder shares, coupled with standard lock-up restrictions and an administrative support agreement charging $10,000 per month, outlines the economic alignment and ongoing burn rate. Citing a going concern qualification due to the reliance on completing a business combination within the prescribed period, auditor MaloneBailey, LLP confirmed the financial statements present a pre-operational entity focused exclusively on the pharmaceutical industry that generates no revenue until a combination closes. Investors must weigh the $201,000,000 trust reserve against the absolute certainty of liquidation if the target search exceeds the 21-month maximum window.

This filing establishes the SPAC's trust account size ($201M), per-share trust value (~$10.05), deadline for a business combination (15 months from closing, i.e., by April 29, 2026, with possible extensions to July 29, 2026), and the terms of sponsor equity (founder shares subject to lock-up and forfeiture if the over-allotment is not exercised). It also confirms standard SPAC provisions: redemption rights for public shareholders, no deal target identified, and sponsor waivers of redemption and liquidation rights on founder shares. For investors tracking redemption deadlines and trust value, the key numbers are the trust per share and the deadline.

Sets the baseline trust value, redemption mechanics, and deadline for investors to monitor. The sponsor’s negligible cost for founder shares creates a potential conflict of interest. The structure includes sponsor-only extension rights without shareholder vote, and a redemption cap that may affect large holders.

For investors tracking the transaction schedule, accelerating the S-1 effectiveness compresses the execution runway, meaning definitive merger documentation and shareholder voting notices will likely follow sooner, which subsequently fixes the timeline for when redemption windows open and close. Management’s explicit request for a late-January effectiveness date signals an intent to finalize the combination without awaiting default review cycles, thereby reducing ambiguity around public share liquidity and capital deployment, while the filing’s strict reliance on statutory disclaimer language clarifies that administrative timing approval carries zero presumption of factual validation regarding the underlying prospectus content.

What changed: Form 8-K current report disclosing Omnibus Amendment No. 3 to the Definitive Merger Agreement between Drugs Made In America Acquisition Corp. and Power Analytics Global Corp. According to the amendment executed by DMAA Chief Executive Officer Roger E. Bendelac and PAGC Executive Chairman Keith Barksdale, DMAA acknowledges a post-extension redemption baseline of 13,559,770 public shares following the redemption of 9,440,230 shares for $99,336,016.67 on April 27, 2026. The agreement mandates the sponsor forfeit not less than 50% of founder shares, subject the remainder to earnout vesting if the closing price equals or exceeds $12.50 and then $15.00, require surrender of 430,000 private placement rights plus cancellation of 45,092 ordinary shares, reset minimum cash to a target of $30,000,000 and a floor of $15,000,000, fix merger consideration calculations to a fully diluted share count and a Reference Price of $10.00, authorize a $0.25 to $0.35 per right tender option, permit a PIPE of up to $150,000,000 alongside $500,000 in convertible notes to BV Advisory Partners LLC and $1,500,000 in working capital loans, establish an outside date of February 26, 2027 (with a hard business combination deadline of April 29, 2027), and mandate an independent fairness opinion due to an affiliated combination structure. Why it matters: The amendment exposes shareholders to significant dilution and timeline compression while pursuing a strategic expansion into artificial intelligence, advanced analytics, and quantum-resistant security solutions through a potential three-party combination valuing PAGC and an unidentified target together at $3,000,000,000, contingent on a definitive letter of intent by September 30, 2026. Executive compensation is detailed via fixed issuances of 250,000 shares to Roger E. Bendelac and 175,000 shares to Saleem Elmasri, while underwriting arrangements involve a deferred fee restatement with Clear Street LLC and lock-ups for 230,000 representative shares. The $15,000,000 cash floor fundamentally alters redemption calculus by tying available closing cash to valuation adjustments, whereas the pre-approved contingent Amendment No. 4 introduces dual-path execution risks and requires independent disinterested director approval for all structural determinations. These contractual shifts collectively reallocate economic risk away from public shareholders toward the sponsor and placement agents ahead of the proxy solicitation.

What changed: According to the registrant, this is a Form 8-K filed pursuant to Rule 425 under the Securities Act, serving as a written communication transmitting Omnibus Amendment No. 3 to the Definitive Merger Agreement between Drugs Made In America Acquisition Corp. (DMAA) and Power Analytics Global Corp. (PAGC). [MECHANICS] According to the Company in Item 1.01, the Boards of Directors approved the third amendment on July 14, 2026. The filing discloses that on April 27, 2026, shareholders approved charter amendments permitting extensions through April 29, 2027, authorizing monthly deposits of the lesser of $300,000 or $0.04 per non-redeemed public share. Prior redemptions removed 9,440,230 shares for $99,336,016.67, establishing a baseline of 13,559,770 public shares. The amendment mandates the Sponsor forfeit not less than 50% of founder shares, with the remainder subject to earnout vesting triggered at $12.50 and $15.00 closing prices. The Company will surrender 430,000 private placement rights for no consideration and cancel 45,092 ordinary shares corresponding to an unfunded subscription. The parties authorize a $150,000,000 PIPE, a $500,000 convertible note to BV Advisory Partners, LLC, and working capital loans up to $1,500,000. Minimum cash provisions target $30,000,000 with a $15,000,000 floor. The Outside Date is set to February 26, 2027. The parties pre-approve a contingent three-party merger valuing PAGC and an undisclosed Additional Target at $3,000,000,000, contingent on executing a letter of intent and delivering a Designation Notice by September 30, 2026. [SUBSTANCE] PAGC is described as engaged in artificial intelligence, advanced analytics, and quantum-resistant security solutions. The Board previously approved 250,000 executive shares for Roger E. Bendelac and 175,000 for Saleem Elmasri. The deferred underwriting fee stands at $6,900,000 ($6.19 million post-redemption), adjusted against 230,000 representative shares. Disclosed operational conditions include sponsor default, working-capital withdrawals, going-concern qualifications, and material weaknesses. Because PAGC and BV Advisory Partners, LLC share common principal ownership, the Company requires a fairness opinion from an independent firm and mandates that specified determinations be made solely by independent and disinterested directors. Why it matters: Per the mechanics disclosed, the transaction architecture is fundamentally rewritten to strip sponsor economics and fix the fully diluted share count before the S-4/Proxy distribution, replacing open-end dilution with hard caps, forfeiture schedules, and price-contingent vesting. Public shareholders face an imminent $0.25–$0.35 tender, exchange, or consent decision on publicly held rights. The Company's pivot to a $3,000,000,000 dual-target architecture introduces binary execution risk: if the Additional Target achieves PCAOB audit readiness by September 30, 2026, both mergers close simultaneously; otherwise, PAGC closes first and the secondary entity defers. The mandatory independence requirements and fairness opinion shift valuation scrutiny away from affiliated investors. According to the timeline, investors tracking the calendar must monitor the September 30, 2026 structural election and the subsequent proxy solicitation to determine whether the combined valuation framework survives regulatory and board review before the February 26, 2027 Outside Date.

What changed: Joint Filing Agreement. This document is a Joint Filing Agreement executed by Feis Equities LLC and Lawrence M. Feis on June 25, 2026. Regarding redemption deadlines, trust value, extension provisions, merger deal progress, and sponsor conduct, the filing reports no operational changes or updates; it solely permits each signatory to file a Schedule 13G on behalf of the other under Rule 13d-1(k). The filing contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: It operates exclusively as a routine administrative exhibit for beneficial ownership disclosure logistics and carries no binding effect on SPAC economics, transaction timelines, or shareholder rights.

What changed: Quarterly report on Form 10-Q for the period ended March 31, 2026, including unaudited financial statements, MD&A, and subsequent event disclosures. Shareholders approved extension to April 29, 2027, with monthly sponsor deposits of $300k or $0.04 per non-redeemed share. In connection with the vote, holders of 9,440,230 shares (41% of public float) redeemed at ~$10.52 per share, withdrawing $99.3 million from trust. The sponsor acknowledged inability to fulfill financial obligations and defaulted on the share subscription receivable, leaving 45,092 shares subject to cancellation. The Company entered into a $100k interim convertible note with BV Advisory Partners LLC, with potential for $500k total financing and 40% sponsor-level economics. On April 29, 2026, the Company signed a definitive merger agreement with Power Analytics Global Corp. (PAGC). CEO compensation was formalized ($4,500/month, 250,000 shares upon deal close). CFO consulting agreement updated to 175,000 shares. Disclosure controls were found ineffective due to material weakness in segregation of duties and related party controls. Why it matters: The large redemption signals weak public confidence. Sponsor default forces reliance on third-party financing and reduces sponsor alignment. The extension provides runway to July 2027 but requires monthly cash deposits. The definitive merger with PAGC indicates a concrete de-SPAC target; however, the target's business (AI/ML/quantum analytics/cybersecurity) is disclosed only via a letter of intent and merger agreement. Trust value per share remains ~$10.52 for remaining public shareholders. The material weakness in internal controls and sponsor's financial distress are risks to deal completion.

What changed: This document is a Limited Power of Attorney (presented as Exhibit A and Exhibit B) executed pursuant to the Securities Exchange Act of 1934 to authorize designated agents to sign and submit a Schedule 13G with the SEC on behalf of Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC regarding holdings in DMAA. Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct, the filing text reports no changes. According to the document, signed executives at Mizuho dated 5-14-2026 formally granted Takahiro Katsura full power and authority to execute the Form 13G, finalize amendments, restatements, supplements, and exhibits, and timely file them with the SEC. The document attributes standard liability disclaimers to the attorneys-in-fact, specifying they assume no responsibility or liability for failing to comply with Section 13 of the Exchange Act on behalf of the undersigned entities. Why it matters: As a routine compliance exhibit attached to a Schedule 13G filing, it matters only for confirming Mizuho’s internal delegation of signature authority to meet Section 13(d) and 13(g) reporting obligations. Per the document, there are no claims about DMAA’s customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Because it contains no updated trust mechanics, redemption windows, merger timelines, or sponsor behavior observations, it carries no direct material impact on investor decisions regarding the SPAC’s pending transaction or liquidation pathways.

What changed: A Form 425 written communication filing submitted pursuant to Rule 425 under the Securities Act, accompanied by a Current Report on Form 8-K that discloses a Definitive Merger Agreement dated April 29, 2026, and two subsequent amendments executed on April 30, 2026, between Drugs Made In America Acquisition Corp. ('DMAA') and Power Analytics Global Corp ('PAGC'). According to the Merger Agreement, the parties have moved from negotiation to a binding combination framework. The agreement establishes a Valuation Milestone Schedule where PAGC’s enterprise valuation targets $1.0 billion if verified revenue contracts reach $75M+, scales to $750 million for $50M–$75M contracts, reaches $500 million for $25M–$50M contracts, and sets a Floor Valuation of $300 million for $15M–$25M contracts; the agreement states that falling below $300 million permits renegotiation or termination. DMAA represents that it will use commercially reasonable efforts to deliver cash at closing through the Trust Account net of redemptions, taxes, and expenses, and/or PIPE financing. The parties acknowledge a target minimum cash level of $30,000,000, with flexibility to close at levels not less than $15,000,000, subject to corresponding adjustments to valuation and ownership. The agreement explicitly notes that cash availability varies depending on redemption levels. Post-closing ownership expects approximately 90% held by former PAGC shareholders and approximately 10% by existing DMAA shareholders prior to PIPE dilution, though Section 3.2 marks the exact exchange ratio as TBD pending the Registration Statement. The outside date is set at twelve months from the agreement date, extendable by mutual agreement for up to two additional three-month periods. Governance shifts to directors and officers designated by PAGC at closing. Amendment No. 1 corrects the governing law to the State of Delaware for the agreement while preserving Cayman Islands law for DMAA’s internal corporate governance, and clarifies termination provisions. Amendment No. 2 completes notice addresses, listing DMAA’s Chief Executive Officer Roger E. Bendelac at 420 Lexington Avenue, Suite 1402, New York, NY 10170 with email rbendelac@protonmail.com, and PAGC’s Executive Chairman Keith Barksdale at 903 Hudson Street, Hoboken, NJ 07030 with email kbarksdale@poweranalytics.com. Why it matters: Redemption mechanics directly threaten the $30,000,000 target and the $15,000,000 hard floor; the agreement explicitly ties insufficient closing cash to potential valuation adjustments or termination, meaning high redemption rates could shrink the public float’s residual stake or abort the deal entirely. Because the exchange ratio remains unspecified and the Valuation Milestone Schedule adjusts equity splits based on validated contract value rather than a static valuation, public shareholders face uncertainty over whether their approximate 10% stake will be diluted or adjusted downward if contract milestones are missed. PAGC warrants that it will deliver an intellectual property schedule, evidence of an active GSA CAGE Code, and a debt-free condition, creating operational and compliance hurdles that could delay or prevent closing even if shareholder approval passes. Transferring executive leadership and board composition entirely to PAGC designees removes sponsor oversight post-close. The indemnification structure limits recovery to a Fifteen percent cap of the Closing Valuation with a Five Hundred Thousand United States Dollars deductible, and general representations survive only eighteen months. All projections regarding the $1.0 billion target, ownership percentages, and pipeline timing are expressly qualified as forward-looking statements based on the current expectations of DMAA and PAGC management, and the filing warns they are not guarantees of actual performance.

What changed: Form 8-K disclosing a Definitive Merger Agreement between Drugs Made In America Acquisition Corp. (DMAA) and Power Analytics Global Corp (PAGC), including Amendment No. 1 and Amendment No. 2 executed on April 30, 2026. According to the agreement, DMAA will merge with PAGC, a Delaware corporation focused on artificial intelligence, advanced analytics, and quantum-resistant security solutions, with the surviving entity targeting Nasdaq listing. Regarding redemption and trust mechanics, the parties acknowledge a target minimum cash level of $30,000,000 available at closing from the Trust Account (net of redemptions, taxes, and expenses) and/or PIPE financing, with explicit contractual flexibility to close at amounts not less than $15,000,000, which would trigger corresponding adjustments to valuation and ownership percentages. The closing is subject to a twelve-month outside date from the April 29, 2026 agreement date, extendable by mutual written consent for up to two additional three-month periods. Post-closing ownership prior to PIPE dilution is expected to be approximately ninety percent held by former PAGC shareholders and ten percent by existing DMAA shareholders, with the target enterprise valuation set at One Billion United States Dollars ($1,000,000,000) but scaled downward based on a Valuation Milestone Schedule measuring verified, signed, and enforceable revenue contracts down to a Floor Valuation of Three Hundred Million United States Dollars ($300,000,000), below which either party may elect to renegotiate or terminate. On other substantive terms, the filing clarifies that the exact exchange ratio will be determined upon final capitalization and SEC Registration Statement effectiveness, PAGC must deliver an intellectual property schedule and evidence of an active GSA CAGE Code, and post-closing directors and officers will be designated by PAGC. Indemnification protections carry a Five Hundred Thousand United States Dollars ($500,000) deductible, an eighteen-month survival period for representations, and a liability cap of fifteen percent of the Closing Valuation, excluding fraud or willful misconduct. Chief Executive Officer Roger E. Bendelac and Executive Chairman Keith Barksdale executed the agreements, which now govern disputes under Delaware law with exclusive jurisdiction in the Court of Chancery of the State of Delaware. Why it matters: For redemption-tracking investors, the mechanical link between the $1,000,000,000 headline valuation and actual contract milestones means that Trust Account payout ratios directly influence whether the enterprise value breaches the $300,000,000 floor, potentially activating termination rights without requiring a proxy defeat. The ability to close with as little as $15,000,000 alters traditional redemption modeling, indicating the deal can survive significant outflows but will proportionally compress the exchange ratio and dilute remaining public shareholders once final capitalization and any PIPE rounds are priced. The hard twelve-month closing calendar removes standard extension ambiguity, establishing a definitive liquidation or consummation deadline that forces a binary resolution by mid-2027 unless the parties exercise the permitted extension windows. Shifting board control entirely to PAGC’s designees concentrates integration risk around the target’s operational capacity to maintain federal contracting eligibility via the GSA CAGE Code requirement and execute the contracted revenue stream, while the explicit exclusion of delivered contracts as a standalone closing condition reduces immediate deal-breaker risk but leaves downstream valuation realization dependent on third-party payment performance rather than guaranteed milestone attainment.

What changed: Form 8-K Current Report disclosing shareholder approval of a charter amendment to extend the business combination deadline, concurrent public share redemptions, and associated Trust Account adjustments. Per the Company's April 27, 2026 extraordinary general meeting record, shareholders approved an extension proposal moving the business combination deadline up to twelve months from April 29, 2026 to April 29, 2027 in one-month increments. The Board concurrently approved an initial one-month extension to May 29, 2026. In connection with the vote, 9,440,230 public shareholders exercised redemption rights, prompting the removal of $99,336,016.67 (approximately $10.52 per share) from the Trust Account. Following the redemption, 24,276,913 ordinary shares remain outstanding, including 13,559,770 sold in the initial public offering. The filing states the sponsor must deposit the lessor of $300,000 or $0.04 per non redeemed public share for each monthly extension, while Exhibit 3.1 formally amends the charter to reference a $0.02 per non-redeemed public share monthly deposit schedule through April 29, 2027. Why it matters: The immediate outflow of $99,336,016.67 significantly shrinks the capital base available to execute a business combination before the new April 2027 expiration. The mandatory monthly extension deposits create a recurring capital drain that sponsors must fund to maintain corporate existence, directly impacting post-combination equity value. The voting record—18,906,281 FOR against 4,892,646 AGAINST, achieving a 70.58% quorum—confirms strong shareholder turnout and explicit approval to continue operations despite the substantial cash reduction.

What changed: SEC Form 8-K current report disclosing the entry into material definitive agreements (a routine compliance exhibit updating executive compensation and amended consulting arrangements). This filing reports no modifications to the redemption calendar, trust account valuation, extension timeline, merger closing deadline, or sponsor conduct protocols. The deal status remains announced without a scheduled shareholder vote or payout trigger. Regarding deal mechanics, the document establishes post-closing settlement terms for leadership equity: shares referenced in these agreements are earmarked to be issued at the closing of the initial business combination within ten (10) days thereafter, conditional on the prior execution of a definitive agreement. No amendments to redemption price, maximum extension provisions, or public float maintenance rules are disclosed. Why it matters: Beyond deal mechanics, the filing substantively restructures leadership compensation and corporate liability exposure, as stated by the Company. For Chief Financial Officer Saleem Elmasri (initially appointed November 17, 2025), the amended Statement of Work with Titan Advisory Services LLC retains operational duties at $3,500 monthly compensation, confirms unpaid amounts accrue as binding obligations, and adjusts equity compensation because Titan was never issued the originally stipulated 100,000 ordinary shares. The updated grant awards Elmasri 175,000 ordinary shares. For Chief Executive Officer Roger Bendelac (appointed February 28, 2026), whose compensation was initially undetermined, the Company executed a separate agreement with Aleutian Equity Holdings LLC. Bendelac receives $4,500 per month, broken down as $2,500 payable currently and up to $2,000 deferrable based on the Company’s cash flow, with deferred sums accruing as binding obligations. He is additionally allocated 250,000 ordinary shares. According to Exhibit 10.2, the agreement specifies indemnification covering securities claims (excluding gross negligence/fraud), limits liability to fees paid except in cases of fraud or willful misconduct, and requires dispute resolution through mediation followed by binding arbitration via AAA or JAMS in New York under New York governing law. These terms introduce specific cashflow-dependent liabilities and transaction-contingent share issuances that alter the post-merger capital stack, governance framework, and sponsorship cost structure.

What changed: Schedule 14A Amendment No. 1 to a Revised Definitive Proxy Statement updating voting thresholds, extension timelines, and sponsor disclosures. The Company reports the outstanding Ordinary Share count increased from 33,517,143 to 33,717,143. Accordingly, the required affirmative votes for the Extension Proposal dropped from 11,827,619 to 11,760,953 Public Shares, and the Adjournment Proposal requirement fell from 6,241,429 to 6,141,429 Public Shares. Annex A replaces Article 48.7: the Business Combination deadline is reset to April 29, 2027, and the monthly Trust Account deposit obligation was revised to 'the lesser of $300,000 or $0.04 per non-redeemed Public Share' (previously cited as '$0.02'). The filing discloses that Drugs Made In America Acquisition LLC holds sponsor shares, with Lynn Stockwell identified as the managing member exercising voting and dispositive power, while she disclaims beneficial ownership except for her pecuniary interest. Why it matters: These amendments directly govern redemption mechanics and capital preservation ahead of the Extraordinary General Meeting. Pushing the final deal deadline to April 29, 2027 and adjusting the monthly trust funding metric to $0.04 or $300,000 changes the cash-outflow pressure and extends the redemption window relative to the prior structure. Revised share counts and voting minimums alter the exact number of un-redemmed public shares required to approve the extension and satisfy quorum rules. Beyond procedural math and timeline shifts, the document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, or litigation.